Trial Profile
Study EGF107671 - a phase II study of lapatinib plus topotecan or lapatinib plus capecitabine in the treatment of recurrent brain metastases from ErbB2 [HER2]-positive breast cancer following cranial radiotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Topotecan (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Dec 2011 Results published in the Journal of Neuro-Oncology.
- 23 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Nov 2009 Planned end date changed from 1 Jul 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.